Tumor Necrosis Factor Related Activation Protein
Tumor Necrosis Factor Related Activation Protein Uses, Dosage, Side Effects, Food Interaction and all others data.
Tumor Necrosis Factor Related Activation Protein is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
| Trade Name | Tumor Necrosis Factor Related Activation Protein |
| Generic | Dapirolizumab pegol |
| Dapirolizumab pegol Other Names | Dapirolizumab pegol, Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Tumor Necrosis Factor Related Activation Protein
